A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Completed · Phase 1 · NCT05241834
Conditions: Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
At a glance
- Research payments reported, 2025
- $666,697
- U.S. investigators named
- 12
- Sites paid
- 11
- Planned or actual enrollment
- 70
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LOXO-260 (drug)
- Dates
- Started 2022-03-23; completion 2026-06-03
- Results posted
- Not yet
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.
From ClinicalTrials.gov, last updated 2026-08-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $666,697 in research payments for this study in 2025 (12 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Edward B. Garon, MD Hematology & Oncology · Los Angeles, CA
- Hyunseok Kang, MD Medical Oncology · Stanford, CA
- Dong M. Shin, M.D. Medical Oncology · Atlanta, GA
- Christine M. Bestvina, M.D. Medical Oncology · Chicago, IL
- Lori J. Wirth, MD Medical Oncology · Boston, MA
- Francis P. Worden, MD Medical Oncology · Ann Arbor, MI
- Jared M. Weiss, M.D. Hematology & Oncology · Chapel Hill, NC
- Alexander Edward D. Drilon, MD Medical Oncology · New York, NY
- Vineeth K. Sukrithan, MD Medical Oncology · Columbus, OH
- Marcia S. Brose, MD Medical Oncology · Philadelphia, PA
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Sarina A. Piha-paul, M.D. Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute LLC $234,054
- Ut MD Anderson Cancer Center $169,154
- Memorial Sloan-Kettering $91,884
- University of Michigan Health System, MI $42,736
- University of Chicago $37,357
- The Ohio State University $24,149
- Emory University Hospital, GA $18,637
- University of North Carolina at Chapel Hill $17,230
- Dana Farber PArtners Cancer Care Inc $14,416
- Ronald Reagan UCLA Medical Center, CA $11,172
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $5,907
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.